Stabilitech
iosBio is a UK-based biotechnology company dedicated to developing innovative oral, thermostable vaccines for major infectious diseases. Utilizing proprietary platforms like OraPro™, Enhanced Surface Display (ESD™), and AI-driven antigen design, iosBio aims to revolutionize vaccination by making it more accessible, cost-effective, and efficient. The company's mission is to create vaccines that offer significant advantages over traditional methods, including oral delivery that is stable at ambient temperatures, enabling rapid and global deployment. iosBio's leadership team brings extensive experience in biotechnology, vaccine development, and business, committed to transforming global health through next-generation vaccines.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Thermostable oral vaccine delivery platform (OraPro)
Platform formulation and capsule-based delivery that stabilises viral vector vaccines for oral release in the lower small intestine, intended to induce mucosal and systemic immunity without cold-chain requirements.
Enhanced antigen surface display platform
Platform technology that modifies antigen processing to increase cell-surface display density and persistence of vaccine antigens, intended to accelerate and strengthen immune responses and enable dose-sparing or single-dose potential.
Orally delivered thermostable EBV vaccine candidate (lead clinical candidate)
Lead vaccine program designed as an orally administered, thermostable viral-vector vaccine targeting Epstein-Barr Virus, reported to have shown strong preclinical antibody responses and being prepared for Phase 1 clinical evaluation.
Thermostable oral vaccine delivery platform (OraPro)
Platform formulation and capsule-based delivery that stabilises viral vector vaccines for oral release in the lower small intestine, intended to induce mucosal and systemic immunity without cold-chain requirements.
Enhanced antigen surface display platform
Platform technology that modifies antigen processing to increase cell-surface display density and persistence of vaccine antigens, intended to accelerate and strengthen immune responses and enable dose-sparing or single-dose potential.
Orally delivered thermostable EBV vaccine candidate (lead clinical candidate)
Lead vaccine program designed as an orally administered, thermostable viral-vector vaccine targeting Epstein-Barr Virus, reported to have shown strong preclinical antibody responses and being prepared for Phase 1 clinical evaluation.
Services
Commercial licensing of oral thermal-stabilisation technology and associated delivery formats to external vaccine developers for oral/sublingual administration of viral vector vaccines.
Computational antigen screening and optimisation workflow to generate antigen variants with improved immunogenicity, stability and manufacturability for vaccine programs.
Commercial licensing of oral thermal-stabilisation technology and associated delivery formats to external vaccine developers for oral/sublingual administration of viral vector vaccines.
Computational antigen screening and optimisation workflow to generate antigen variants with improved immunogenicity, stability and manufacturability for vaccine programs.
Expertise Areas
- Oral vaccine development
- Thermostable vaccine formulation and CMC
- Antigen engineering and presentation
- AI-driven antigen design
Key Technologies
- Thermal stabilisation for oral formulations (up to 50°C)
- Oral/sublingual capsule delivery targeting lower small intestine
- Non-replicating adenoviral vector platforms
- Enhanced antigen surface display
News & Updates
iosBio awarded a £288,000 grant from the UK government to support the development of an oral Nipah virus vaccine using its proprietary OraPro™ technology.
iosBio licenses its OraPro™ platform technology to ImmunityBio for the oral delivery of their COVID-19 vaccine candidate, enabling oral administration of thermally stable viral vectors.
iosBio announces the appointment of Dr. Craig Laferrière to lead the development and execution of the company's pipeline strategy.
An article discussing the potential of oral vaccines in combating COVID-19 and the advantages they offer over traditional vaccines.
iosBio awarded a £288,000 grant from the UK government to support the development of an oral Nipah virus vaccine using its proprietary OraPro™ technology.
iosBio licenses its OraPro™ platform technology to ImmunityBio for the oral delivery of their COVID-19 vaccine candidate, enabling oral administration of thermally stable viral vectors.
iosBio announces the appointment of Dr. Craig Laferrière to lead the development and execution of the company's pipeline strategy.
An article discussing the potential of oral vaccines in combating COVID-19 and the advantages they offer over traditional vaccines.